基本信息
浏览量:3
职业迁徙
个人简介
Description of Research Expertise
Immuno-gene Therapy for Thoracic Malignancies
Lung cancer and other thoracic malignancies are the leading cause of cancer deaths in the United States today. The Thoracic Oncology Research Laboratory is focusing on the design of new treatment strategies for lung cancer and mesothelioma based on the rapidly evolving disciplines of molecular biology, immunotherapy, and gene therapy.
Dr. Albelda’s research is translational in focus and includes animal models, work with human tumor samples, and the conduct of clinical trials. This work is primarily funded through a recently renewed Program Project from the National Cancer Institute and participation in a number of RO1 grants.
The tumor microenvironment is one area of active study. Studies are underway with the goals of 1) a better understanding of the biology of the tumor microenvironment with a focus on the immunuosuppressive activities of white blood cells and fibroblasts, 2) novel approaches to alter the tumor microenvironment to enhance immunotherapy including studying effects using COX-2 inhibitors, TGFbeta inhibitors, T-regulatory cell inhibitors., antibodies against B-cells, and chemotherapeutic drugs. A second area of interest in the lab is the use of adoptive T cell transfer to treat lung malignancies. Studies are underway to modify T cells in order to make them traffic more efficiently into tumors, to have better killing function, and to resist inactivation by the tumor microenvironment. A T cells targeting cancer-associated fibroblasts is being developed. In addition, Dr. Albelda is closely involved with a number of immunogene clinical trials at Penn using an adenovirus expressing the immune-activator interferon-alpha that is instilled into the pleural space of mesothelioma patients (in collaboration with Dr. Daniel Sterman) and T cells altered to attack the mesothelioma tumor target, mesothelin (in collaboration with Drs. Carl June and Andrew Haas).
Immuno-gene Therapy for Thoracic Malignancies
Lung cancer and other thoracic malignancies are the leading cause of cancer deaths in the United States today. The Thoracic Oncology Research Laboratory is focusing on the design of new treatment strategies for lung cancer and mesothelioma based on the rapidly evolving disciplines of molecular biology, immunotherapy, and gene therapy.
Dr. Albelda’s research is translational in focus and includes animal models, work with human tumor samples, and the conduct of clinical trials. This work is primarily funded through a recently renewed Program Project from the National Cancer Institute and participation in a number of RO1 grants.
The tumor microenvironment is one area of active study. Studies are underway with the goals of 1) a better understanding of the biology of the tumor microenvironment with a focus on the immunuosuppressive activities of white blood cells and fibroblasts, 2) novel approaches to alter the tumor microenvironment to enhance immunotherapy including studying effects using COX-2 inhibitors, TGFbeta inhibitors, T-regulatory cell inhibitors., antibodies against B-cells, and chemotherapeutic drugs. A second area of interest in the lab is the use of adoptive T cell transfer to treat lung malignancies. Studies are underway to modify T cells in order to make them traffic more efficiently into tumors, to have better killing function, and to resist inactivation by the tumor microenvironment. A T cells targeting cancer-associated fibroblasts is being developed. In addition, Dr. Albelda is closely involved with a number of immunogene clinical trials at Penn using an adenovirus expressing the immune-activator interferon-alpha that is instilled into the pleural space of mesothelioma patients (in collaboration with Dr. Daniel Sterman) and T cells altered to attack the mesothelioma tumor target, mesothelin (in collaboration with Drs. Carl June and Andrew Haas).
研究兴趣
论文共 461 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Translational Lung Cancer Researchno. 4 (2024): 956-960
Sunil Singhal,Abhishek S Rao,Jason Stadanlick, Kyle Bruns,Neil T Sullivan, Andres Bermudez, Adam Honig-Frand, Ryan Krouse, Sachinthani Arambepola, Emily Guo,Edmund K Moon,George Georgiou,
Cancer research (2024)
Caitlin M Tilsed, Barzan A Sadiq,Tyler E Papp, Phurin Areesawangkit, Kenji Kimura,Estela Noguera-Ortega,John Scholler, Nicholas Cerda,Haig Aghajanian, Adrian Bot,Barbara Mui,Ying Tam,
Proceedings of the National Academy of Sciences of the United States of Americano. 13 (2024): e2319856121-e2319856121
Nature Reviews Clinical Oncologyno. 1 (2024): 47-66
crossref(2023)
Andrew R Haas, Ryan J Golden,Leslie A Litzky,Boris Engels,Linlin Zhao,Fangmin Xu, John A Taraszka,Melissa Ramones,Brian Granda,Wan-Jung Chang,Julie Jadlowsky, Kim-Marie Shea,
Zvi G. Fridlender,George Buchlis,Veena Kapoor,Guanjun Cheng,Jing Sun,Sunil Singhal, M. Cecilia Crisanti,Liang-Chuan S. Wang,Daniel Heitjan, Linda A. Snyder,Steven M. Albelda
crossref(2023)
Andrew V. Kossenkov,Anil Vachani, Celia Chang,Calen Nichols, Shere Billouin, Wenhwai Horng,William N. Rom,Steven M. Albelda,Michael K. Showe,Louise C. Showe
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn